漢思集團(00554.HK)獲善水資本斥逾千萬增持
漢思集團(00554.HK)宣布,上周三(18日)獲善水資本以每股均價0.3059元,增持3,460萬股普通股股份,涉及價值約1,058.41萬元。增持後,善水資本最新持股股數為3.14億股,股權由6.59%升至7.4%。
自2020年,集團夥拍善水資本牽頭的國際財團,透過匯達交通入主香港「城巴」及「新巴」兩家專營巴士公司後,新管理團隊推行了一系列措施,除重組巴士路線、引入自動化提升營運效率,亦完成兩個專營權的合併,實現更強的協同效應。
此外,匯達交通積極開拓新的收入渠道,如推出「觀光城巴」捕捉訪港旅客的商機,並藉著啟德體育園在內的大型活動機遇爭取廣告合作,從多方面提升業務表現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.